Methotrexate pharmacogenomics in rheumatoid arthritis: introducing false-positive report probability.


In this issue of the Journal, Lee and associates [1] investigated the contribution of candidate polymorphisms in folate and purine pathways to disease activity in RA patients treated with low-dose MTX therapy. This cross-sectional study analysis in patients enrolled in the BRASS (Brigham and Women’s Hospital Rheumatoid Arthritis Sequential Study) cohort… (More)
DOI: 10.1093/rheumatology/kep060


1 Figure or Table